RT Journal Article
SR Electronic
T1 Development and validation of a stakeholder-driven, self-contained electronic informed consent platform for trio-based genomic research studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.01.24306461
DO 10.1101/2024.05.01.24306461
A1 Norton, Bethany Y
A1 Liu, James
A1 Lewis, Sara A
A1 Magee, Helen
A1 Kruer, Tyler N
A1 Dinh, Rachael
A1 Bakhtiari, Somayeh
A1 Nordlie, Sandra H.
A1 Shetty, Sheetal
A1 Heim, Jennifer
A1 Nishiyama, Yumi
A1 Arango, Jorge
A1 Johnson, Darcy
A1 Seabrooke, Lee
A1 Shub, Mitchell
A1 Rosenberg, Robert
A1 Shusterman, Michele
A1 Wisniewski, Stephen
A1 Cooper, Blair
A1 Rothwell, Erin
A1 Fahey, Michael C
A1 Shrader, M. Wade
A1 Lennon, Nancy
A1 Oleszek, Joyce
A1 Pierce, Wendy
A1 Fleming, Hannah
A1 Belthur, Mohan
A1 Tinto, Jennifer
A1 Noritz, Garey
A1 Glader, Laurie
A1 Steffan, Kelsey
A1 Walker, William
A1 Grenard, Deborah
A1 Aravamuthan, Bhooma
A1 Bjornson, Kristie
A1 Joseph, Malin
A1 Gross, Paul
A1 Kruer, Michael C
A1 the Cerebral Palsy Research Network.
YR 2024
UL http://medrxiv.org/content/early/2024/05/03/2024.05.01.24306461.abstract
AB Increasingly long and complex informed consents have yielded studies demonstrating comparatively low participant comprehension and satisfaction with traditional face-to-face approaches. In parallel, interest in electronic consents for clinical and research genomics has steadily increased, yet limited data are available for trio-based genomic discovery studies. We describe the design, development, implementation, and validation of an electronic iConsent application for trio-based genomic research deployed to support genomic studies of cerebral palsy. iConsent development incorporated stakeholder perspectives including researchers, patient advocates, institutional review board members, and genomic data-sharing considerations. The iConsent platform integrated principles derived from prior electronic consenting research and elements of multimedia learning theory. Participant comprehension was assessed in an interactive teachback format. The iConsent application achieved nine of ten proposed desiderata for effective patient-focused electronic consenting for genomic research.Overall, participants demonstrated high comprehension and retention of key human subjects’ considerations. Enrollees reported high levels of satisfaction with the iConsent, and we found that participant comprehension, iConsent clarity, privacy protections, and study goal explanations were associated with overall satisfaction. Although opportunities exist to optimize iConsent, we show that such an approach is feasible, can satisfy multiple stakeholder requirements, and can realize high participant satisfaction and comprehension while increasing study reach.Competing Interest StatementPaul Gross is President and CEO of the CP Research Network, which contributed to the funding of this project. Mr. Gross personally made financial contributions (donations) to CPRN to support this work, but receives no financial compensation related to either. Dr. Noritz has consulted for Abbott Nutrition, unrelated to this project. Dr. Shrader receives research funding from NIH and serves on the National Advisory Board for Medical Rehabilitative Research for NIH/NICHD. The remaining authors declare no conflict of interest. Clinical Protocols https://www.noprotocolurl.com Funding StatementFunding Statement MCK was supported by the National Institute of Neurological Disorders and Stroke (NINDS) (1R01 NS106298 and NS127108). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Phoenix Children's IRB reviewed and approved this study as the single IRB. Informed consent was obtained from all participants. Although participant level phenotypic data were not included in our analysis, these de-identified data were obtained for the trio-based genomic study through collaboration with the CPRN registry.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesParticipant informed consent authorizes sharing of de-identified data with researchers for research purposes only. Anonymized survey data will be made available upon reasonable request to the corresponding author. https://www.nodataavailabilityurl.com